Biktarvy – Talk Bio

FDA Places Clinical Hold on Five Gilead HIV Studies Due to Safety Concerns

3 months ago talkbio0Tagged Biktarvy, CD4 + T-cell, Clinical Trials, Gilead Sciences, GS-1720, GS-4182, HIV, Lenacapavir, Lymphocyte Count measurement, safety signal, Study on Hold, United States Food and Drug Administration

FDA; Gilead Sciences; HIV; clinical hold; GS-1720; GS-4182; clinical trials; safety signal; CD4+ T-cell; lymphocyte count; Biktarvy; lenacapavir

ICER Report Highlights Unjustified Price Hikes on Five Brand-Name Drugs, Costing U.S. $815 Million in 2023

9 months ago talkbio0Tagged Biktarvy, Cabometyx, CREM gene, Darzalex, drug price, Entresto, Increased, Johnson & Johnson, Novartis, pharmaceutical companies, Prices

ICER, unsupported price increases, drug price hikes, pharmaceutical companies, Gilead Sciences, Johnson & Johnson, Novartis, Biktarvy, Darzalex, Entresto, Cabometyx, Xeljanz.

Gilead Sciences Surpasses Q3 Earnings and Sales Forecasts, Boosts Annual Outlook

10 months ago talkbio0Tagged Advice, annual, Biktarvy, earnings, Gilead Sciences, HIV, HIV Prevention, Lenacapavir, Veklury

Gilead Sciences, Q3 earnings, HIV drug sales, annual guidance, Biktarvy, Veklury, lenacapavir, HIV prevention

GSK’s Dovato Matches Efficacy of Gilead’s Biktarvy with Less Weight Gain in HIV Trial

1 year ago talkbio0Tagged Biktarvy, DOBLE, Dovato, Gilead, HIV, PASO, SmithKline Beecham, Spanish, Spanish Language, ViiV Healthcare

GSK, Dovato, Gilead, Biktarvy, HIV, weight gain, Spanish trial, PASO DOBLE, ViiV Healthcare